Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Repair Windows errors before they cause bigger problems3Scan for outdated or missing drivers - takes under a minuteNo. Pfizer did not move to Ireland through its proposed $160 billion merger with Allergan: the deal was terminated before it closed. The plan would have kept Allergan’s Irish legal domicile and placed the combined company’s principal executive offices in Ireland, while its global operational headquarters remained in New York. Pfizer forecast a lower adjusted tax rate on foreign-generated earnings, but said U.S.-based income would still face U.S. corporate tax.
What the proposed merger would have done
Pfizer and Allergan announced the proposed transaction on November 23, 2015. Pfizer described it as having an approximate $160 billion enterprise value, calculated using Pfizer’s November 20 closing share price of $32.18 and an indicated value of $363.63 per Allergan share. That was an announced valuation, not a final cash price or the value of a completed acquisition. Pfizer’s announcement set out the proposed terms.
![[Brandon Turner]-The Book on Rental Property Investing- How to Create Wealth and Passive Income Through Intelligent Buy & Hold Real Estate Investing! (SoftCover)](https://m.media-amazon.com/images/I/51mMR6cQZCL._SL160_.jpg)
The combined business was to operate under Allergan plc, which would be renamed Pfizer plc after closing. Three different details about its location matter:
- Legal domicile: Allergan’s Irish legal domicile would remain.
- Principal executive offices: These would be in Ireland.
- Global operational headquarters: These would be in New York.
So “Pfizer moves to Ireland” is misleading if it suggests the company planned to relocate its operating headquarters, workforce, or all its business activity there. The proposal changed the combined company’s legal domicile and principal executive-office location; its global operations headquarters was still designated for New York.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →#1 Best Overall
- WHAT'S INCLUDED: 110 durable (3"x5") flashcards covering all the essential aspects of fundamental analysis. Learn to analyze financial statements, key ratios, valuation metrics, and stock evaluation techniques like a pro. Plus, get 1 month of exclusive access to an online training and research platform focused on fundamental analysis for evaluating companies. Simply scan the QR code on your thank-you card to access your digital content.
- MASTER DEFINITIVE INVESTMENT PRINCIPLES, SUITABLE FOR INVESTORS AND TRADERS, Providing a Clear Roadmap for Understanding Financial Metrics and Analyzing Stocks.
- DISCOVER THE POWER OF QUICK STUDY CARDS: An Effective Alternative to Lengthy Books. They Deliver Precise, Focused Information on Financial Metrics and Stock Analysis, Making Learning Fun and Efficient for Investors and Traders.
- INSTANTLY RECOGNIZE STOCK VALUATION TRENDS AND IDENTIFY HIDDEN OPPORTUNITIES with Strategies Most Investors and Traders Overlook.
- DON'T WASTE TIME ON LOW-PROBABILITY INVESTING STRATEGIES. Focus on Learning High Probability, High Payout Strategies for Optimal Investing Success.
Why Ireland mattered to the tax plan
Pfizer projected that the combined company’s adjusted effective tax rate would be approximately 17%–18% by the first full year after closing. This was Pfizer’s forecast, not an achieved rate. In transaction materials filed with the SEC, Pfizer said the change would affect the expected rate on earnings generated outside the United States. Pfizer also said the transaction would not change the tax rate paid on U.S.-based income and that the company would remain subject to U.S. corporate tax on that income. The filed transaction communication describes that distinction.
In other words, the proposal was intended to reduce the expected tax burden on foreign earnings, not to eliminate all U.S. taxes or make U.S.-based income exempt from U.S. corporate tax. Because the merger never closed, the projected rate cannot be treated as Pfizer’s actual tax rate under the proposed structure, and the available transaction evidence does not establish realized savings from it.
Was the merger blocked by anti-inversion rules?
The proposed deal was widely discussed as an inversion strategy because it would have retained an Irish legal domicile while Pfizer was the larger U.S. company. But that public description should not be confused with a formal finding that anti-inversion rules blocked a completed merger.
The Congressional Research Service explains that the proposed Pfizer–Allergan merger was not covered by the anti-inversion rules because Pfizer was projected to own 56% of the combined firm. The CRS also says Pfizer ended the deal after Treasury issued regulations on April 4, 2016. Its report on corporate expatriations, inversions, and mergers explains the ownership rationale. The distinction is that the deal was associated with inversion planning, but, according to CRS, it was not covered by those rules on the stated ownership basis.
Why the agreement ended
On April 6, 2016, Pfizer announced that the companies had mutually agreed to terminate the merger agreement. Pfizer said the decision followed U.S. Treasury actions announced on April 4, which the companies concluded qualified as an “Adverse Tax Law Change” under their agreement. That is Pfizer’s account of the contractual trigger, not a separate Treasury characterization. Pfizer also agreed to pay Allergan $150 million for transaction expenses. Pfizer’s termination announcement states those terms.
Ian Read, Pfizer’s chairman and CEO at the time, said: “The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an ‘Adverse Tax Law Change’ under the merger agreement.” The companies therefore abandoned the proposal before the planned Irish-domiciled structure could take effect.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
